Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 167

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range

Bailey, C. J., Iqbal, N., T'joen, C., List, J. F. · 2012 · Diabetes, Obesity and Metabolism

Abstract

Aims: Many patients with type 2 diabetes are suboptimally managed with currently available therapies. Dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, has shown efficacy in reducing diabetic hyperglycaemia. This study assessed efficacy of three lower doses in recently diagnosed patients. Methods: This phase 3, randomized, double‐blind, placebo‐controlled study assigned treatment‐naïve patients to placebo or dapagliflozin monotherapy (1, 2.5 or 5 mg) daily for 24 weeks. Patients were antidiabetic drug‐naïve with inadequate glycaemic control [haemoglobin A1c ( HbA1c ) ≥7.0 and ≤10.0%]. The primary efficacy endpoint was change in HbA1c from baseline. Secondary endpoints included changes in body weight and fasting plasma glucose ( FPG ), and proportions achieving HbA1c <7%. Results: A total of 282 patients with type 2 diabetes were randomly assigned to one of four treatment groups. Baseline characteristics were similar across groups. At week 24, mean HbA1c reduction was significantly greater with dapagliflozin: −0.68% for 1 mg, −0.72% for 2.5 mg, −0.82% for 5 mg, versus 0.02% for placebo (p < 0.0001); compared to mean baseline values of 7.8–8.1%. Mean FPG reduction was significantly greater for all dapagliflozin groups versus placebo (p < 0.02), as was mean weight reduction (p < 0.003). During the treatment period, 19.1% of placebo‐treated patients received rescue medication or discontinued because of poor glycaemic control versus 6.9, 4.1 and 5.9% for dapagliflozin 1, 2.5 and 5 mg, respectively. Percentages of patients experiencing ≥1 adverse event were similar across groups. Conclusion: Dapagliflozin at doses of 1, 2.5 and 5 mg/day is effective in reducing glycaemic levels and body weight in treatment‐naïve patients with type 2 diabetes. Dapagliflozin was generally well tolerated. This insulin‐independent mechanism suggests a new treatment for type 2 diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2012.01659.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 167

Metadata

Authors
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2012-07-24
Volume
14
Issue
10
Pages
951-959
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2001991301
Cited by
167
References
7
FWCI
11.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range. https://app.cochat.ai/papers/10.1111/j.1463-1326.2012.01659.x
The paper
Bailey, C. J., Iqbal, N., T'joen, C., & List, J. F. (2012). Dapagliflozin monotherapy in drug‐naïve patients with diabetes: a randomized‐controlled trial of low‐dose range. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2012.01659.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.